<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>61</patient-age><report-id>US-VERTEX PHARMACEUTICALS INC.-2013-001123</report-id><gender>female</gender><reactions><reaction>Liver cancer</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>VX-950 (Telaprevir)</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>PEGASYS</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>RIBAVIRIN</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Hepatitis C</indication></indications><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>30728_111</messagenumb>
		<messagesenderidentifier>VERTEXP2</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151730</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>US-VERTEX PHARMACEUTICALS INC.-2013-001123</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-22</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-22</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>US-VERTEX PHARMACEUTICALS INC.-2013-001123</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
			<studyname>Solicited Program</studyname>
			<sponsorstudynumb>Solicited - CVS Caremark</sponsorstudynumb>
			<observestudytype>3</observestudytype>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>VERTEXP2</senderorganization>
			<senderdepartment>Global Patient Safety</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>Sean</sendergivename>
			<senderfamilyname>Darcy</senderfamilyname>
			<senderstreetaddress>130 Waverly Street</senderstreetaddress>
			<sendercity>Cambridge</sendercity>
			<senderstate>MA</senderstate>
			<senderpostcode>02139</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<senderemailaddress>VRTXGPS_SubmissionTracking@vrtx.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>Office of Surveillence and Epidemiology</receiverdepartment>
			<receivertitle>Mr.</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receiverfax>3019183134</receiverfax>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>UNKNOWN</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19510304</patientbirthdate>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hepatitis C</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Liver cancer</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Liver, cancer of</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hepatic neoplasm malignant</reactionmeddrapt>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>VX-950 (Telaprevir)</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>201917</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Vertex Pharmaceuticals Inc.</drugauthorizationholder>
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hepatitis C</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-10-05</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-12-28</drugenddate>
				<drugtreatmentduration>85</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>VX-950</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hepatic neoplasm malignant</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hepatic neoplasm malignant</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>PEGASYS</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hepatitis C</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-10-05</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2013-01-22</drugenddate>
				<drugtreatmentduration>110</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PEGINTERFERON ALFA-2A</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>RIBAVIRIN</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hepatitis C</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-10-05</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2013-01-22</drugenddate>
				<drugtreatmentduration>110</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>RIBAVIRIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>A Solicited serious report <Semaphore x="2117205" class="Disease or Finding" value="Liver and Intrahepatic Bile Duct Carcinoma" score="1.00" ID="C7927">of <Semaphore x="2016978" class="AnatomicStructure" value="Hepatic Tissue" score="1.00" ID="C32735">LIVER </Semaphore><Semaphore x="2158390" class="Disease or Finding" value="Malignant Neoplasm" score="1.00" ID="C9305">CANCER </Semaphore></Semaphore>was received from a consumer in USA, concerning a <Semaphore x="1387834" class="Patient Age" value="61" score="1.00" ID=""><Semaphore x="5960701642276865" class="Patient Age" value="61" score="1.00" ID="">61 </Semaphore>year old </Semaphore>female patient participating in a monitored <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>program subsequent to dosing with <Semaphore x="703687" class="Medicine" value="Incivek" score="0.93" ID="195080">Incivek </Semaphore>(<Semaphore x="1250953" class="Medicine" value="telaprevir" score="0.93" ID="195078">telaprevir</Semaphore>), peginterferon and <Semaphore x="1133532" class="Medicine" value="Ribavirin" score="0.93" ID="297021">ribavirin</Semaphore>.No past medical history or concomitant medications were provided.On 05 October 2012, the patient received <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore><Semaphore x="703687" class="Medicine" value="Incivek" score="0.93" ID="195080">Incivek </Semaphore>(<Semaphore x="1250953" class="Medicine" value="telaprevir" score="0.93" ID="195078">telaprevir</Semaphore>) tablets, peg interferon and <Semaphore x="1133532" class="Medicine" value="Ribavirin" score="0.93" ID="297021">ribavirin </Semaphore>(dosage <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">regimen </Semaphore>for all of which was not provided) for <Semaphore x="2020151" class="Disease or Finding" value="Hepatitis C Infection" score="1.00" ID="C3098">Hepatitis C</Semaphore>. The patient received unspecified doses of <Semaphore x="703687" class="Medicine" value="Incivek" score="0.93" ID="195080">Incivek </Semaphore>(<Semaphore x="1250953" class="Medicine" value="telaprevir" score="0.93" ID="195078">telaprevir</Semaphore>), peg interferon and <Semaphore x="1133532" class="Medicine" value="Ribavirin" score="0.93" ID="297021">ribavirin </Semaphore>before the onset of the event.On an unspecified date, the patient developed <Semaphore x="2117205" class="Disease or Finding" value="Liver and Intrahepatic Bile Duct Carcinoma" score="1.00" ID="C7927">liver <Semaphore x="3127610" class="MedDRA LLT" value="Neoplasm malignant" score="1.00" ID="10028997">cancer </Semaphore></Semaphore>(assessed as medically significant). On 28-Dec 2012, the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>with <Semaphore x="703687" class="Medicine" value="Incivek" score="0.93" ID="195080">Incivek </Semaphore>(<Semaphore x="1250953" class="Medicine" value="telaprevir" score="0.93" ID="195078">telaprevir</Semaphore>) was completed while on 22 January 2013, the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>with <Semaphore x="1002327" class="Medicine" value="peginterferon alfa-2a" score="0.74" ID="213119">peginterferon alfa 2a </Semaphore>and <Semaphore x="1133532" class="Medicine" value="Ribavirin" score="0.93" ID="297021">ribavirin </Semaphore>was discontinued.The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore><Semaphore x="2117205" class="Disease or Finding" value="Liver and Intrahepatic Bile Duct Carcinoma" score="1.00" ID="C7927">of the event <Semaphore x="2117205" class="Disease or Finding" value="Liver and Intrahepatic Bile Duct Carcinoma" score="1.00" ID="C7927">of <Semaphore x="2117205" class="Disease or Finding" value="Liver and Intrahepatic Bile Duct Carcinoma" score="1.00" ID="C7927">liver <Semaphore x="3127610" class="MedDRA LLT" value="Neoplasm malignant" score="1.00" ID="10028997">cancer </Semaphore></Semaphore></Semaphore></Semaphore>was not resolved at the time of this report.</narrativeincludeclinical>
				<sendercomment>The serious event of malignant hepatic neoplasm is unexpected for telaprevir.  Limited information precludes a meaningful assessment of the case.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>